| Christopher Caldarone, MD | |
|
6701 Fannin Street, Houston, TX 77030 | |
| (832) 824-1000 | |
| Not Available |
| Full Name | Christopher Caldarone |
|---|---|
| Gender | Male |
| Speciality | Thoracic Surgery (cardiothoracic Vascular Surgery) |
| Location | 6701 Fannin Street, Houston, Texas |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124504113 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208G00000X | Thoracic Surgery (cardiothoracic Vascular Surgery) | 32538 (Iowa) | Primary |
| Entity Name | Children's Physician Services Of South Texas |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568658227 PECOS PAC ID: 3678478872 Enrollment ID: O20040324001704 |
News Archive
With equal access to medical care and medication, Hispanic men and women have as good or greater chance as non-Hispanics of controlling their high blood pressure, researchers reported in Hypertension: Journal of the American Heart Association.
Acute myeloid leukemia, a common leukemia in adults, is characterized by aberrant proliferation of cancerous bone marrow cells. Activating mutations in a protein receptor known as FLT3 receptor are among the most prevalent mutations observed in acute myeloid leukemias. FLT3 mutants are thought to activate several signaling pathways that contribute to cancer development.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that its applications for ALN-TTR01 have been given clearance by Portuguese, Swedish, and British regulatory authorities to begin clinical testing. The trial will begin enrolling patients shortly in a blinded, randomized, placebo-controlled, multicenter Phase I study.
Covagen and Tanabe Research Laboratories U.S.A, Inc., a fully owned subsidiary of Mitsubishi Tanabe Pharma Corporation, today announced that they expanded their strategic research collaboration. MTPC and TRL have nominated a first bispecific FynomAb for formal preclinical development which triggered an undisclosed milestone payment. MTPC and TRL also exercised an option for a second bispecific FynomAb program based on the parties' research and licensing agreement signed in October 2012.
In a huge victory for ALS sufferers, FDA granted Genervon Biopharmaceuticals a fast track designation for its first in class highly effective multi-target master regulator biotechnology drug GM604 for ALS. FDA said it met the necessary criteria.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Christopher Caldarone, MD 2450 Holcombe Blvd, Ste Nb-34l, Houston, TX 77021 Ph: (832) 828-3660 | Christopher Caldarone, MD 6701 Fannin Street, Houston, TX 77030 Ph: (832) 824-1000 |
News Archive
With equal access to medical care and medication, Hispanic men and women have as good or greater chance as non-Hispanics of controlling their high blood pressure, researchers reported in Hypertension: Journal of the American Heart Association.
Acute myeloid leukemia, a common leukemia in adults, is characterized by aberrant proliferation of cancerous bone marrow cells. Activating mutations in a protein receptor known as FLT3 receptor are among the most prevalent mutations observed in acute myeloid leukemias. FLT3 mutants are thought to activate several signaling pathways that contribute to cancer development.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that its applications for ALN-TTR01 have been given clearance by Portuguese, Swedish, and British regulatory authorities to begin clinical testing. The trial will begin enrolling patients shortly in a blinded, randomized, placebo-controlled, multicenter Phase I study.
Covagen and Tanabe Research Laboratories U.S.A, Inc., a fully owned subsidiary of Mitsubishi Tanabe Pharma Corporation, today announced that they expanded their strategic research collaboration. MTPC and TRL have nominated a first bispecific FynomAb for formal preclinical development which triggered an undisclosed milestone payment. MTPC and TRL also exercised an option for a second bispecific FynomAb program based on the parties' research and licensing agreement signed in October 2012.
In a huge victory for ALS sufferers, FDA granted Genervon Biopharmaceuticals a fast track designation for its first in class highly effective multi-target master regulator biotechnology drug GM604 for ALS. FDA said it met the necessary criteria.
› Verified 9 days ago
Dr. Michael S Sweeney, M.D., Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 6400 Fannin St, Ste 3000, Houston, TX 77030 Phone: 713-790-0841 Fax: 713-790-1350 | |
Eyal E Porat, M.D. Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 1200 Binz St Ste 900, Houston, TX 77004 Phone: 713-522-0220 Fax: 833-989-1160 | |
Stephen G. Swisher, M.D. Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 1515 Holcombe Blvd, Houston, TX 77030 Phone: 713-792-6161 | |
Dr. Steven B. Eisenberg, M.D. Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 6411 Fannin St, Houston, TX 77030 Phone: 713-850-1190 Fax: 713-850-1327 | |
Mahesh Ramchandani, MD Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 6550 Fannin St, Suite 1401, Houston, TX 77030 Phone: 713-441-5200 Fax: 713-793-7428 | |
David A. Ott, M.D. Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Not Enrolled in Medicare Practice Location: 1101 Bates Ave, P115, Houston, TX 77030 Phone: 832-355-4900 Fax: 832-355-3770 | |
Ara A. Vaporciyan, M.D. Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 1515 Holcombe Blvd, Houston, TX 77030 Phone: 713-792-6161 |